Moligand™,10mM in DMSO Moligand™ for sensitive chromatographic and analytical workflows requiring minimal baseline interference.
Store at -80°C Ships Dry ice packs + Cold packs Check lot-specific COA for exact specifications.
SDS, COA, datasheet, and spec sheet available for download. Lot-specific COA accessible via lot number lookup.
Cited in 0 peer-reviewed publications across chromatography, organic synthesis, and cross-coupling reactions.
LR-90 is an advanced glycation end product (AGE) inhibitor, inhibits inflammatory responses in human monocytes LR-90 is also used in the research of diabetic animal model .
In Vitro
LR-90 (0, 25, 50, 100, and 200 μM) inhibits RAGE, MCP-1, COX-2, IP-10 and NOX2 mRNA expression in THP-1 cells in a dose-dependent manner, after pretreatment 1 h befor S100b stimulatation for 4 hours. LR-90 (0, 25, 50, 100, and 200 μM) dose-dependently and significantly blocks THP-1 cells adherence to endothelial cells after pretreatment 1 h befor S100b stimulatation for 24 hours. LR-90 (0, 25, 50, 100, and 200 μM, for 24 hours) shows no effect on the cell viability of THP-1 cells. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability AssayCell Line: THP-1 cells Concentration: 0, 25, 50, 100, and 200 μM Incubation Time: 24 hours Result: Showed no cytotoxicity to THP-1 cells. RT-PCRCell Line: THP-1 cells Concentration: 0, 25, 50, 100, and 200 μM Incubation Time: One hour before S100b addition for 4 hours Result: Dose-dependently inhibited mRNA expression of RAGE, MCP-1, COX-2, IP-10, and NOX2 stimulated with S100b.
In Vivo
LR-90 (50 mg/L, p.o. for 27 weeks) significantly reduces plasma lipids, modestly affects hyperglycaemia in ZDF rats. LR-90 (50 mg/L) decreases renal AGE, AGER and lipid peroxidation. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Male ZDF rats (13 to 40 weeks)Dosage: 50 mg/L Administration: P.O. for 27 weeks Result: Significantly reduced plasma triacylglycerol and cholesterol by ∼55% and ∼30%, respectively. Modestly affected hyperglycaemia and blood pressure. Lowered the body weight.
IC50& Target:AGE
| Isomères SMILES | CC(C)(C(=O)O)OC1=CC=C(C=C1)NC(=O)NC2=C(C=C(C=C2)CC3=CC(=C(C=C3)NC(=O)NC4=CC=C(C=C4)OC(C)(C)C(=O)O)Cl)Cl |
|---|---|
| PubChem CID | 10212249 |
| Poids moléculaire | 709.57 |
Comprehensive hazard, handling, storage, and regulatory compliance document.
Download SDS →Lot-specific quality data. Enter your lot number to retrieve the exact COA.
Look up COA →Full quality attributes and acceptance criteria for this grade.
View spec sheet →Our grade selection guide covers purity, stabilizer status, and application suitability for all variants in our catalog.
View Moligand™ grade guide →
